Azamian Bobak R. sold $803K of TARS (indirect holdings)
Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at $80.31 ($0.80M total) on 2026-11-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on CEO/Chair selling activity, but it does not include new company performance, guidance, or regulatory/clinical milestones.
Market read
This is a routine insider-sale filing with modest sentiment relevance, not a fundamental catalyst.
What to watch
Traders may over-weight insider sales; the key is whether there are concurrent news catalysts (earnings, trial results, financing) which are not present in this filing excerpt.
Background
The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.
Ticker impact
SEC Form 4 shows Tarsus Pharmaceuticals CEO/Chair Azamian Bobak R. sold 10,000 shares at $80.31 on a 10b5-1 plan.
Likely limited, with any downside pressure fading as the market treats the sale as routine 10b5-1 execution.
The filing is a primary SEC Form 4 disclosure, but the transaction is explicitly under a pre-arranged 10b5-1 plan and is not accompanied by new operational or guidance information.
Market effects
Minimal, as this is a single-company insider sale with no stated sector-wide regulatory or clinical update.
None.
None.
Counterpoint
Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than any change in fundamentals, so price impact may be negligible.
Key entities
- issuerTarsus Pharmaceuticals, Inc.
US-listed company whose CEO/Chair executed a 10b5-1 open-market sale disclosed on Form 4.
- insiderAzamian Bobak R.
President/CEO and Board Chair who sold 10,000 shares indirectly under a pre-arranged 10b5-1 plan.


